SAB Biotherapeutics (NASDAQ: SABS) net income
SAB Biotherapeutics reported a net profit of $13.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $34.1m. Earnings per share were $0.22.
SAB Biotherapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 4 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $13.3m | — | — | $0.22 |
| 2024 | −$34.1m | — | −2,579.0% | −$3.68 |
| 2023 | −$42.2m | — | −1,884.5% | −$7.64 |
| 2022 | −$18.7m | — | −78.4% | −$0.43 |
| 2021 | −$17.1m | −185.2% | −28.2% | −$0.63 |
| 2020 | $20.1m | — | 36.4% | $0.79 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
SAB Biotherapeutics net income compared with its sector
By net income for its latest fiscal year, SAB Biotherapeutics ranks 157th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 155th | LifeMD | $14.4m | 7.4% |
| 156th | Pro-DEX | $13.7m | 17.6% |
| 157th | SAB Biotherapeutics | $13.3m | — |
| 158th | NRC Health | $11.6m | 8.4% |
| 159th | Electromed | $11.3m | 15.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of SAB Biotherapeutics
- How much did SAB Biotherapeutics earn in fiscal 2025?
- SAB Biotherapeutics reported a net profit of $13.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $34.1m.
- What are the earnings per share of SAB Biotherapeutics?
- They were $0.22 in fiscal 2025, compared with −$3.68 in fiscal 2024.
- What was the most profitable year for SAB Biotherapeutics?
- Of its last 6 fiscal years, fiscal 2020, with $20.1m.
- Where does SAB Biotherapeutics rank in its sector by net income?
- It ranks 157th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for SAB Biotherapeutics come from?
- From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on SAB Biotherapeutics: the SAB Biotherapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.